Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Juçara (Euterpe Edulis Martius) Supplementation Effect in Muscle Protection, Performance and Soreness in Lower Limbs After Exercise-Induced Muscle Damage

7 mei 2026 bijgewerkt door: Fábio Juner Lanferdini, Universidade Federal de Santa Maria

Juçara (Euterpe Edulis Martius) Supplementation Effect in Muscle Protection, Performance and Soreness in Lower Limbs After Exercise-Induced Muscle Damage: A Six-Week Randomized, Triple-Blind, Placebo-Controlled Clinical Trial

The purpose of this study is to find out if taking a natural supplement made from the Juçara fruit (a Brazilian berry rich in antioxidants called anthocyanins) can help the body recover faster after damage caused by exercise. Researchers want to see if Juçara can reduce muscle soreness and help muscles regain their strength and quality more quickly compared to a placebo (a "dummy" pill with no active ingredients).

What happens during the study? The study included 24 healthy, active men. It was a "crossover" study, meaning every participant tried both the Juçara supplement and the placebo at different times.

Supplement Phase: Participants took 12 capsules a day for 7 days.

Muscle Damage Test: To cause temporary muscle damage, participants performed a specific jumping protocol (100 maximal jumps).

Recovery Monitoring: Researchers tracked the participants for 72 hours after the jumps to measure:

How high they could jump (strength/performance).

Muscle soreness (using a pain scale).

Muscle "quality" and stiffness (using ultrasound imaging).

Wait Period: After the first phase, participants waited 14 days (washout) before switching to the other supplement to repeat the process.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

24

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Rio Grande do Sul
      • Santa Maria, Rio Grande do Sul, Brazilië, 97105900
        • Centro de Educação Física e Desportos

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Males
  • Aged 18-40 years
  • Physically active, defined as performing at least three exercise sessions per week according to IPAQ questionnaire
  • No history at lower-limb within the previous six months
  • No medical restrictions for maximal exercise testing
  • No allergy to red fruits
  • No physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol
  • No history of lower-limb surgery
  • No use nutritional supplements within 30 days prior to study initiation
  • Abstention from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol.

Exclusion Criteria:

  • Individuals younger than 18 or older than 40 years
  • Not physically active, defined as performing fewer than three exercise sessions per week according to IPAQ questionnaire
  • Presence of history at lower-limb injury within the previous six months
  • Presence of medical restrictions for maximal exercise testing
  • Known allergy to red fruits
  • Presence of physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol
  • History of lower-limb surgery
  • Use of nutritional supplements within 30 days prior to study initiation
  • Inability to abstain from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Juçara group
The sample consisted of 24 healthy, physically active men with any kind of experience in any physical exercise modality. Eligibility criteria were as follows: (1) male, aged 18-40 years; (2) physically active, defined as performing at least three exercise sessions per week according to IPAQ questionnaire; (3) no history at lower-limb within the previous six months; (4) no medical restrictions for maximal exercise testing; (5) no allergy to red fruits; (6) no physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol; (7) no history of lower-limb surgery; (8) no use nutritional supplements within 30 days prior to study initiation; and (9) abstention from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol.
Total of 11 separate occasions under the Juçara condition. A familiarization session of CMJ and EIMD protocol (10 sets of CMJ repetitions with 1-minute rest between sets) was performed, followed by a 14-day washout period. During this visit, volunteers' descriptive data were assessed. On day 1 of this condition (72h pre EIMD), body mass was obtained, and participants received the supplementation (Juçara) to be consumed for 7 days (one capsule every 12 h). On day 2, the CSA from QUAD and HAMS, elastography from vastus lateralis (VL) and biceps femoris long head (BFlh) of the dominant limb, and the CMJ performance were assessed. After that, participants performed the EIMD protocol. Follow-up assessments were conducted at 24 h (day 3), 48 h (day 4), and 72 h (day 5) post-EIMD, repeating the same measurements. A 14-day washout period separated the two interventions.
Placebo-vergelijker: Placebo Group
The sample consisted of 24 healthy, physically active men with any kind of experience in any physical exercise modality. Eligibility criteria were as follows: (1) male, aged 18-40 years; (2) physically active, defined as performing at least three exercise sessions per week according to IPAQ questionnaire; (3) no history at lower-limb within the previous six months; (4) no medical restrictions for maximal exercise testing; (5) no allergy to red fruits; (6) no physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol; (7) no history of lower-limb surgery; (8) no use nutritional supplements within 30 days prior to study initiation; and (9) abstention from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol.
Total of 11 separate occasions under the placebo condition. A familiarization session of CMJ and EIMD protocol (10 sets of CMJ repetitions with 1-minute rest between sets) was performed, followed by a 14-day washout period. During this visit, volunteers' descriptive data were assessed. On day 1 of this condition (72h pre EIMD), body mass was obtained, and participants received the supplementation (placebo) to be consumed for 7 days (one capsule every 12 h). On day 2, the CSA from QUAD and HAMS, elastography from vastus lateralis (VL) and biceps femoris long head (BFlh) of the dominant limb, and the CMJ performance were assessed. After that, participants performed the EIMD protocol. Follow-up assessments were conducted at 24 h (day 3), 48 h (day 4), and 72 h (day 5) post-EIMD, repeating the same measurements. A 14-day washout period separated the two interventions.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Countermovement Jump Height
Tijdsspanne: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Countermovement Jump (CMJ) hieght will be measured to assess using two force plates (AMTI OR6-6-2000; 1000 Hz). Measurements will be obtained at Baseline (Pre), and at 24, 48, and 72 hours following the exercise induced muscle damage (EIMD) protocol. Data will be expressed in centimeters (cm). Jump height will be calculated using take-off velocity and projectile motion principles.
From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Contermovement jump power
Tijdsspanne: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Countermovement Jump (CMJ) power will be evaluated using two force plates (AMTI OR6-6-2000; 1000 Hz). Peak power will be calculated based on the jump flight time or force-time curve. Assessments will be performed at Baseline (Pre), 24h, 48h, and 72h post exercise induced muscle damage. Data will be expressed in Watts (W). Power during the concentric phase (i.e., the propulsive phase; interval between the onset of propulsion and take-off) will be calculated by multiplying force by velocity.
From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Quadriceps and hamstrings Echointensity
Tijdsspanne: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Quadriceps and Hamstrings muscle echointensity will be assessed using ultrasonography to evaluate muscle damage. Images will be analyzed through gray-scale histogram analysis using ImageJ software. Assessments will be performed at Baseline (Pre-exercise), and at 24 hours, 48 hours, and 72 hours following the exercise-induced muscle damage (EIMD) protocol. Data will be expressed in arbitrary units (AU).
From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Quadriceps and Hamstrings Cross-Sectional Area
Tijdsspanne: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol
Muscle Cross-Sectional Area from Quadriceps and Hamstrings will be assessed using an ultrasound with extended field of view mode at 50% of limb length. Quadriceps and Hamstrings Cros-Sectional areas will be expressed in cm².
From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol
Vastus Lateralis and Biceps Femoris Long Head stiffness
Tijdsspanne: From pre Exercise Muscle Damage Protocol to Post-72h Exercise Induced Muscle Damage protocol.
Vastus Lateralis and Biceps Femoris Long Head muscle stiffness will be assessed using Shear Wave Elastography mode from an ultrasound. Muscle stiffness will be expressed in kilopascal (kPa).
From pre Exercise Muscle Damage Protocol to Post-72h Exercise Induced Muscle Damage protocol.
Quadriceps and Hamstrings muscle soreness
Tijdsspanne: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Muscle soreness of the quadriceps will be assessed using a Visual Analogue Scale (VAS). Measurements will be obtained at Baseline (Pre-exercise), Immediately Post-exercise, 24 hours, 48 hours, and 72 hours following the Exercise Induced Muscle Damage (EIMD) protocol. Data will be expressed on a scale from 0 (no soreness) to 30 centimeters (worst possible soreness).
From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

3 juni 2024

Primaire voltooiing (Werkelijk)

3 oktober 2024

Studie voltooiing (Werkelijk)

2 december 2024

Studieregistratiedata

Eerst ingediend

30 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

7 mei 2026

Eerst geplaatst (Werkelijk)

13 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

7 mei 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 6.753.984
  • UFSM (Andere identificatie: UFSM)

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren